After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...